rv-nyeso tcr pbmc
Cell therapyexperimental
Clinical trial activity
6 trials · 9 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 26, 2017 (NCT03240861)
Timeline
Indications
Studied for
- Anemia, Refractory · Phase 2
- Biomarkers · Phase 1
- Graft vs Host Disease · Early Phase 1
- HIV Infections · Phase 2
- Leukemia, Megakaryoblastic, Acute · Phase 2
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Phase 2
- Leukemia, Myeloid, Acute · Phase 2
- Lymphoma · Phase 2
- Lymphoma, Non-Hodgkin · Phase 2
- Multiple Myeloma · Phase 1
- Myelodysplastic Syndromes · Phase 2
- Neoplasms · Phase 1
- Pancreatic Neoplasms · Phase 1
- Precursor Cell Lymphoblastic Leukemia-Lymphoma · Phase 2
- Recurrence · Phase 1
- Sarcoma · Phase 1
Mechanism of action
- Cancer/testis antigen 1Immunity, passive
Cancer/testis antigen 1 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06849921 | N/A | Nov 7, 2024 | Jiao Tong University |
| NCT06158139 | Phase 1 | Jun 30, 2024 | University of North Carolina at Chapel Hill |
| NCT04744116 | Early Phase 1 (Phase 1) | Feb 17, 2021 | National Cancer Institute (NCI), University of Texas at Houston |
| NCT04083170 | Phase 2 | Sep 30, 2019 | National Heart, Lung, and Blood Institute (NHLBI), University of Washington |
| NCT03506802 | Phase 1 | Sep 1, 2018 | Novartis, University of California, Los Angeles |
| NCT03240861 | Phase 1 | Jul 26, 2017 | California Institute for Regenerative Medicine (CIRM), University of California, Los Angeles |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of California, Los Angeles | Academic/Hospital | 2 | 2 | 1 | 2017 |
| California Institute for Regenerative Medicine (CIRM) | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Jiao Tong University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2021 |
| National Heart, Lung, and Blood Institute (NHLBI) | Government | 1 | 0 | 1 | 2019 |
| Novartis | For profit | 1 | 0 | 1 | 2018 |
| University of North Carolina at Chapel Hill | Academic/Hospital | 1 | 1 | 1 | 2024 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2021 |
| University of Washington | Academic/Hospital | 1 | 1 | 1 | 2019 |
9 organizations
Page 1 / 1